JE is a viral infection caused by the bite of Culex tritaeniorhynchus mosquito. The prevention from the mosquito bites is the key preventive measure for the disease. Most of the individuals suffering from JE do not show clinical symptoms; whereas, the individuals in whom the symptoms develop show signs of neurologic symptoms, weakness, and movement disorders after 10–15 days.
Download the sample report at: https://www.pharmaproff.com/request-sample/1224
As per the current scenario, there is no marketed products available for the primary treatment of JE. Symptomatic treatment and vaccines for prior immunizations are available to prevent the disease from infecting the people.
According to the research findings, majority of pipeline drug candidates are being developed to be administered by intravenous route. It has been observed that intravenous route of medications is dependable and possesses reproducible effects. Moreover, the entire administered dose reaches the systemic circulation immediately increasing the bioavailability of drug.
Get the detailed analysis at: https://www.pharmaproff.com/report/japanese-encephalitis-therapeutics-pipeline
Companies that are involved in developing therapeutics for JE have shown active participation in strategic collaborations to boost up the development of their candidates for JE. For instance, in November 2015, Intercell USA Inc. entered into distribution and marketing services agreement with VaxServe Inc., a Sanofi Pasteur company. Under the terms of the agreement, VaxServe Inc. performed marketing and promotional services and distributed Valneva’s Japanese encephalitis vaccine in the U.S.
Technical advancements in the JE therapeutics development are expected to trigger the growth of the JE therapeutics market. For instance, Intercell’s Antigen Identification Program identifies novel antigens from a variety of pathogens, which are believed to induce the strongest response from the human immune system; thus, providing a viable basis for the further potential development of novel and more powerful prophylactic and therapeutic vaccines and antibody treatments.
Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1224
Some of the key players involved in the development of Japanese Encephalitis therapeutics in the late- and mid-stage include Biological E. Limited, Bharat Biotech Ltd., Valneva SE, Sanofi-aventis Groupe, Indian Immunologicals Ltd., Abivax SA, Ennaid Therapeutics LLC, and Kineta Inc.
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Toll-free: +1-888-778-7886 (USA/Canada)
Email: [email protected]